All Stories

  1. Epidemiological Shifts in Visceral Leishmaniasis Incidence, Relapse, and Mortality in Brazil, 2007–2023: Analysis Using the National Notifiable Diseases Information System
  2. Model-guided geospatial surveillance system for antimalarial drug resistance
  3. Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review
  4. Optimal Long-Acting Antimalarial Regimens for Seasonal Malaria Chemoprevention: Mapping Review and Network Meta-Analysis
  5. Time From Symptom Onset to Treatment Initiation in Visceral Leishmaniasis In Brazil, 2007–2023: A National Notifiable Disease Registry-Based Study
  6. Adaptive Geospatial Surveillance System for Antimalarial Drug Resistance
  7. Blood transfusion in the care of patients with visceral leishmaniasis: a review of practices in therapeutic efficacy studies
  8. Does acute malnutrition in young children increase the risk of treatment failure following artemisinin-based combination therapy? A WWARN individual patient data meta-analysis
  9. Estimating the proportion of relapse following treatment of Visceral Leishmaniasis: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic review
  10. Sudan Ebola virus (SUDV) outbreak in Uganda, 2022: lessons learnt and future priorities for sub-Saharan Africa
  11. Protocol for a systematic review of the evidence-based knowledge on the distribution, associated risk factors, the prevention and treatment modalities for noma
  12. Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990–2020
  13. Definitions matter: Heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis
  14. Infectious diseases data observatory (IDDO) visceral leishmaniasis library of clinical therapeutic studies: A protocol for a living systematic review of clinical studies
  15. The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions.
  16. Improving anthelmintic treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of individual participant data
  17. Systematic review of the scrub typhus treatment landscape: Assessing the feasibility of an individual participant-level data (IPD) platform
  18. The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform
  19. Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans
  20. Preprints in times of COVID19: the time is ripe for agreeing on terminology and good practices
  21. WHO COVID-19 therapeutic guidelines – Authors' reply
  22. Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis
  23. Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans
  24. Systematic review of the scrub typhus treatment landscape: Assessing the feasibility of an individual participant-level data (IPD) platform
  25. Guidelines should not pool evidence from uncomplicated and severe COVID-19
  26. Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis
  27. A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?
  28. Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: A systematic review and meta-analysis
  29. A Systematic Literature Review of Microscopy Methods Reported in Malaria Clinical Trials
  30. The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
  31. Global estimation of anti-malarial drug effectiveness for the treatment of uncomplicated Plasmodium falciparum malaria 1991–2019
  32. Safety and efficacy of the Russian COVID-19 vaccine: more information needed
  33. Febrile illness mapping—much of the world without data and without evidence-based treatments
  34. Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Africa, 1980–2015
  35. Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Southern Asia and South-eastern Asia, 1980–2015
  36. Towards harmonization of microscopy methods for malaria clinical research studies
  37. Efficacy of Single-Dose Primaquine With Artemisinin Combination Therapy on Plasmodium falciparum Gametocytes and Transmission: An Individual Patient Meta-Analysis
  38. Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis
  39. Drug treatments for covid-19: living systematic review and network meta-analysis
  40. The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: A Live, Open-Access Database of Plasmodium Treatment Efficacy Trials
  41. Baseline results of a living systematic review for COVID-19 clinical trial registrations
  42. Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
  43. COVID-19 and risks to the supply and quality of tests, drugs, and vaccines
  44. A living systematic review protocol for COVID-19 clinical trial registrations
  45. The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world?
  46. Publisher Correction: In emergencies, health research must go beyond public engagement toward a true partnership with those affected
  47. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data
  48. In emergencies, health research must go beyond public engagement toward a true partnership with those affected
  49. Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting
  50. The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis
  51. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
  52. Efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a protocol for systematic review and individual patient data (IPD) meta-analysis
  53. Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether‐Lumefantrine for Uncomplicated Malaria
  54. A pooled analysis of the duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine
  55. Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis
  56. The effect of dose on the antimalarial efficacy of artesunate-mefloquine against Plasmodium falciparum malaria: a protocol for systematic review and individual patient data (IPD) meta-analysis
  57. Optimal Duration of Follow-up for Assessing Antimalarial Efficacy in Pregnancy: A Retrospective Analysis of a Cohort Followed Up Until Delivery on the Thailand–Myanmar Border
  58. Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study
  59. Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data
  60. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis
  61. Malaria control in India: A national perspective in a regional and global fight to eliminate malaria
  62. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis
  63. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review
  64. Complex interactions between malaria and malnutrition: a systematic literature review
  65. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
  66. Secondary analysis and participation of those at the data source
  67. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use
  68. Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing
  69. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis
  70. Malaria and Nutritional Status Among Children With Severe Acute Malnutrition in Niger: A Prospective Cohort Study
  71. An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000
  72. Molecular markers of resistance to amodiaquine plus sulfadoxine–pyrimethamine in an area with seasonal malaria chemoprevention in south central Niger
  73. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape
  74. Methodology of assessment and reporting of safety in anti-malarial treatment efficacy studies of uncomplicated falciparum malaria in pregnancy: a systematic literature review
  75. Systematic literature review and meta-analysis of the efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: methodological challenges
  76. Systematic review of studies generating individual participant data on the efficacy of drugs for treating soil-transmitted helminthiases and the case for data-sharing
  77. Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges
  78. Enumerating the Economic Cost of Antimicrobial Resistance Per Antibiotic Consumed to Inform the Evaluation of Interventions Affecting their Use
  79. Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform
  80. The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials
  81. Precision global health in the digital age
  82. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis
  83. Erratum to: Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data
  84. Evaluating drug resistance in visceral leishmaniasis: the challenges
  85. Artemether-lumefantrine and dihydroartemisinin-piperaquine exert inverse selective pressure on Plasmodium falciparum drug sensitivity associated haplotypes in Uganda
  86. Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia
  87. Efficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger
  88. Beyond open data: realising the health benefits of sharing data: Table 1
  89. Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate–amodiaquine fixed dose combination or artemether–lumefantrine in Liberia
  90. The Schistosomiasis Clinical Trials Landscape: A Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual Participant-Level Data (IPD)
  91. Avoiding Data Dumpsters — Toward Equitable and Useful Data Sharing
  92. Combating poor-quality anti-malarial medicines: a call to action
  93. Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data
  94. A link between poor quality antimalarials and malaria drug resistance?
  95. Ethics in Medicine Quality Surveys
  96. Abundance of megalin and Dab2 is reduced in syncytiotrophoblast during placental malaria, which may contribute to low birth weight
  97. Fake anti-malarials: start with the facts
  98. Understanding the mechanisms and drivers of antimicrobial resistance
  99. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations
  100. Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
  101. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data
  102. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data
  103. Artemisinin resistance in Myanmar – Authors' reply
  104. Past and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventions
  105. The effect of dose on the antimalarial efficacy of artemether–lumefantrine: a systematic review and pooled analysis of individual patient data
  106. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker
  107. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data
  108. Quality assurance of drugs used in clinical trials: proposal for adapting guidelines
  109. The Largest Ebola Outbreak– What Have We Learned So Far
  110. Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria
  111. Artemisinin resistance – modelling the potential human and economic costs
  112. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine
  113. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
  114. Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda
  115. Benefits of a Pharmacology Antimalarial Reference Standard and Proficiency Testing Program Provided by the Worldwide Antimalarial Resistance Network (WWARN)
  116. Mind the gaps - the epidemiology of poor-quality anti-malarials in the malarious world - analysis of the WorldWide Antimalarial Resistance Network database
  117. Estimation of malaria haplotype and genotype frequencies: a statistical approach to overcome the challenge associated with multiclonal infections
  118. International health research monitoring: exploring a scientific and a cooperative approach using participatory action research
  119. Proteogenomic insights into salt tolerance by a halotolerant alpha-proteobacterium isolated from an Andean saline spring
  120. The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data
  121. Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives
  122. Trends in Antimalarial Drug Use in Africa
  123. Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda
  124. Surveillance of Travellers: An Additional Tool for Tracking Antimalarial Drug Resistance in Endemic Countries
  125. Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda
  126. Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia
  127. Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferior...
  128. Infections in Children Admitted with Complicated Severe Acute Malnutrition in Niger
  129. Spatiotemporal mathematical modelling of mutations of the dhps gene in African Plasmodium falciparum
  130. Made in Europe: will artemisinin resistance emerge in French Guiana?
  131. High-Throughput Analysis of Antimalarial Susceptibility Data by the WorldWide Antimalarial Resistance Network (WWARN)In VitroAnalysis and Reporting Tool
  132. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000–2011
  133. Impact of malaria during pregnancy on pregnancy outcomes in a Ugandan prospective cohort with intensive malaria screening and prompt treatment
  134. Early parasitological response following artemisinin-containing regimens: a critical review of the literature
  135. Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems
  136. Mapping the Aetiology of Non-Malarial Febrile Illness in Southeast Asia through a Systematic Review—Terra Incognita Impairing Treatment Policies
  137. Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda
  138. Chloroquine-Resistant Malaria in Travelers Returning from Haiti after 2010 Earthquake
  139. Evaluation of a Rapid Test for the Diagnosis of Cholera in the Absence of a Gold Standard
  140. Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial
  141. Artemether-lumefantrine to treat malaria in pregnancy is associated with reduced placental haemozoin deposition compared to quinine in a randomized controlled trial
  142. Performance of a Histidine-Rich Protein 2 Rapid Diagnostic Test, Paracheck Pf®, for Detection of Malaria Infections in Ugandan Pregnant Women
  143. The Primacy of Public Health Considerations in Defining Poor Quality Medicines
  144. Poor quality vital anti-malarials in Africa - an urgent neglected public health priority
  145. The Threat of Artemisinin-Resistant Malaria
  146. Use of Filter Paper as a Transport Medium for Laboratory Diagnosis of Cholera under Field Conditions
  147. Avidity of Serogroup A Meningococcal IgG Antibodies after Immunization with Different Doses of a Tetravalent A/C/Y/W135 Polysaccharide Vaccine
  148. Evaluation of Combined LED-Fluorescence Microscopy and Bleach Sedimentation for Diagnosis of Tuberculosis at Peripheral Health Service Level
  149. Transmission of Plasmodium vivax in South-Western Uganda: Report of Three Cases in Pregnant Women
  150. Performance of LED-Based Fluorescence Microscopy to Diagnose Tuberculosis in a Peripheral Health Centre in Nairobi
  151. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator
  152. Efficacy and safety of artemether–lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial
  153. Reducing Wasting in Young Children With Preventive Supplementation: A Cohort Study in Niger
  154. Meningitis Dipstick Rapid Test: Evaluating Diagnostic Performance during an Urban Neisseria meningitidis Serogroup A Outbreak, Burkina Faso, 2007
  155. Monitoring antimalarial resistance: launching a cooperative effort
  156. Effectiveness of ready-to-use therapeutic food compared to a corn/soy-blend-based pre-mix for the treatment of childhood moderate acute malnutrition in Niger
  157. Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN)
  158. Global resistance surveillance: ensuring antimalarial efficacy in the future
  159. Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest Region of Guinea: A Cross-Sectional Study
  160. Evaluation of three parasite lactate dehydrogenase-based rapid diagnostic tests for the diagnosis of falciparum and vivax malaria
  161. Field Evaluation of Two Rapid Diagnostic Tests for Neisseria meningitidis Serogroup A during the 2006 Outbreak in Niger
  162. Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis
  163. Prevalence, Risk Factors, and Impact on Outcome of Cytomegalovirus Replication in Serum of Cambodian HIV-Infected Patients (2004-2007)
  164. Prevalence Study of Yaws in the Democratic Republic of Congo Using the Lot Quality Assurance Sampling Method
  165. Outbreak of Hepatitis E Virus Infection in Darfur, Sudan: Effectiveness of Real-Time Reverse Transcription-PCR Analysis of Dried Blood Spots
  166. A Look Back at an Ongoing Problem: Shigella dysenteriae Type 1 Epidemics in Refugee Settings in Central Africa (1993–1995)
  167. No association between human herpesvirus 6 reactivation and cryptococcosis in human immunodeficiency virus-infected patients
  168. Mortality Risk among Children Admitted in a Large-Scale Nutritional Program in Niger, 2006
  169. Effect of Preventive Supplementation With Ready-to-Use Therapeutic Food on the Nutritional Status, Mortality, and Morbidity of Children Aged 6 to 60 Months in Niger
  170. Immunogenicity of Fractional Doses of Tetravalent A/C/Y/W135 Meningococcal Polysaccharide Vaccine: Results from a Randomized Non-Inferiority Controlled Trial in Uganda
  171. Assessing Antimalarial Efficacy in a Time of Change to Artemisinin-Based Combination Therapies: The Role of Médecins Sans Frontières
  172. Bleach Sedimentation: An Opportunity to Optimize Smear Microscopy for Tuberculosis Diagnosis in Settings of High Prevalence of HIV
  173. Research in Complex Humanitarian Emergencies: The Médecins Sans Frontières/Epicentre Experience
  174. Treatment of severe malnutrition with 2-day intramuscular ceftriaxonevs5-day amoxicillin
  175. Bonnes Pratiques Cliniques dans les pays en développement : recommandations en termes d’application
  176. The dynamics of measles in sub-Saharan Africa
  177. World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs
  178. Outbreak of Beriberi in a Prison in Côte D'Ivoire
  179. Prevalence, Determinants of Positivity, and Clinical Utility of Cryptococcal Antigenemia in Cambodian HIV-Infected Patients
  180. Meningitis Serogroup W135 Outbreak, Burkina Faso, 2002
  181. CLONAL RECONQUEST OF ANTIBIOTIC-SUSCEPTIBLE SALMONELLA ENTERICA SEROTYPE TYPHI IN SON LA PROVINCE, VIETNAM
  182. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis
  183. Using European travellers as an early alert to detect emerging pathogens in countries with limited laboratory resources
  184. Unacceptably High Mortality Related to Measles Epidemics in Niger, Nigeria, and Chad
  185. Pharyngeal carriage of Neisseria meningitidis in 2–19-year-old individuals in Uganda
  186. High sensitivity and specificity of the Pastorex® latex agglutination test for Neisseria meningitidis serogroup A during a clinical trial in Niger
  187. Estimating transmission intensity for a measles epidemic in Niamey, Niger: lessons for intervention
  188. A Large Outbreak of Hepatitis E among a Displaced Population in Darfur, Sudan, 2004: The Role of Water Treatment Methods
  189. High Mortality Associated with an Outbreak of Hepatitis E among Displaced Persons in Darfur, Sudan
  190. Outbreak of tetanus cases following the tsunami in Aceh province, Indonesia
  191. Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique☆
  192. Late vaccination reinforcement during a measles epidemic in Niamey, Niger (2003–2004)
  193. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment
  194. Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?
  195. Emerging Salmonella Enteritidis anaerogenic phage type 14b: Outbreak in Norwegian, Swedish and Finnish travellers returning from Greece
  196. Exploring the time to intervene with a reactive mass vaccination campaign in measles epidemics
  197. Validation of single real-time TaqMan® PCR assay for the detection and quantitation of four major genotypes of hepatitis E virus in clinical specimens
  198. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004
  199. Risk factors associated with typhoid fever in Son La province, northern Vietnam
  200. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study
  201. Communicable disease control in a migrant seasonal workers population: A case study in Norway
  202. Effectiveness of Mass Oral Cholera Vaccination in Beira, Mozambique
  203. Genetic heterogeneity of hepatitis E virus in Darfur, Sudan, and neighboring Chad
  204. Case management of a multidrug-resistant Shigella dysenteriae serotype 1 outbreak in a crisis context in Sierra Leone, 1999–2000
  205. Cholera in Mozambique, Variant ofVibrio cholerae
  206. Gastro-enteritis outbreak among Nordic patients with psoriasis in a health centre in Gran Canaria, Spain: a cohort study
  207. Outbreak of Salmonella Livingstone infection in Norway and Sweden due to contaminated processed fish products
  208. Emergence of new SalmonellaEnteritidis phage types in Europe? Surveillance of infections in returning travellers
  209. Shigella dysenteriae serotype 1 in west Africa: intervention strategy for an outbreak in Sierra Leone
  210. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development
  211. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda
  212. Detection of a previously uncommon salmonella phage in tourists returning from Europe
  213. Health situation of refugees in Eastern Zaire